ANAB

AnaptysBio's stock price has been significantly impacted by several key events including a substantial beat in its fourth-quarter 2025 financial results, the spin-off of its biopharma operations into First Tracks Biotherapeutics, the approval of a $100 million stock repurchase program, a favorable ruling from the Delaware Chancery Court dismissing Tesaro's anticipatory breach claim, and the publication of pivotal Phase 3 data for Imsidolimab in NEJM Evidence. These events contributed to a significant increase in the stock price. Upcoming events include an FDA decision for Imsidolimab targeted for December 2026 and a trial in July 2026 to adjudicate AnaptysBio's contract claims and right to seek reversion of Jemperli against Tesaro/GSK.